目的 探討宮炎康膠囊聯(lián)合頭孢他啶治療慢性盆腔炎的安全性和有效性。方法 選取2019年1月-2019年8月在商丘市中醫(yī)院治療的慢性盆腔炎患者105例，隨機分成對照組（52例）和治療組（53例）。對照組患者靜脈滴注注射用頭孢他啶，2 g加入250 mL生理鹽水，2次/d；治療組患者在對照組基礎(chǔ)上口服宮炎康膠囊，6粒/次，2次/d。兩組患者均連續(xù)治療14 d。觀察兩組患者臨床療效，同時比較治療前后兩組患者VAS評分、臨床癥狀評分、盆腔炎性包塊直徑，以及血清超敏C反應蛋白（hs-CRP）、糖類抗原125（CA125）、轉(zhuǎn)化生長因子-β1（TGF-β1）水平。結(jié)果 治療后，對照組臨床有效率為82.69%，顯著低于治療組的96.23%（P<0.05）。治療后，兩組患者VAS評分、臨床癥狀評分以及盆腔炎性包塊直徑均顯著降低（P<0.05），且治療組這些指標明顯低于對照組（P<0.05）。治療后，兩組患者血清hs-CRP、CA125較治療前顯著下降（P<0.05），而TGF-β1水平顯著升高（P<0.05）；且治療后治療組患者hs-CRP、CA125、TGF-β1水平明顯好于對照組（P<0.05）。治療組患者的復發(fā)率為1.89%，明顯低于對照組的13.46%（P<0.05）。結(jié)論 宮炎康膠囊聯(lián)合注射用頭孢他啶治療慢性盆腔炎療效確切，可顯著減輕機體炎癥和下腹部疼痛，具有一定的臨床推廣應用價值。

Objective To explore the safety and efficacy of Gongyankang Capsules combined with ceftazidime in treatment of chronic pelvic inflammatory disease. Methods Patients (105 cases) with chronic pelvic inflammatory disease in Shangqiu City Hospital of TCM from January 2019 to August 2019 were randomly divided into control (52 cases) and treatment (53 cases) groups. Patients in the control group were iv administered with Ceftazidime for injection, 2 g added into 250 mL normal saline, twice daily. Patients in the treatment group were po administered with Gongyankang Capsules on the basis of the control group, 6 grains/time, twice daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the VAS score, clinical symptom score, pelvic inflammatory mass diameter, the serum levels of hs-CRP, CA125, TGF-β1 in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 82.69%, which was significantly lower than 96.23% in the treatment group (P < 0.05). After treatment, the VAS score, clinical symptom score, pelvic inflammatory mass diameter in two groups were significantly decreased (P < 0.05), and these indexes in the treatment group were significantly lower than that in the control group (P < 0.05). After treatment, the serum levels of hs-CRP and CA125 in two groups were significantly decreased (P < 0.05), but the TGF-β1 levels were significantly increased (P < 0.05), and the levels of hs-CRP, CA125, TGF-β1 in the treatment group were significantly better than those in the control group (P < 0.05). The recurrence rate of 1.89% in the treatment group was significantly lower than 13.46% in the control group (P < 0.05). Conclusion Gongyankang Capsules combined with ceftazidime in treatment of chronic pelvic inflammatory disease is effective, and can significantly reduce the inflammation and abdominal pain, which has a certain clinical application value.

R984